The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat

Documenti analoghi

• A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis
  di: Javier Armisen, et al.
  Pubblicazione: (2025)
• A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
  di: Jane Knöchel, et al.
  Pubblicazione: (2024)
• Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants
  di: Xue‐Qing Li, et al.
  Pubblicazione: (2024)
• Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects
  di: Shawn Flanagan, et al.
  Pubblicazione: (2024)
• Matlab code for PDX analysis (Doroszko, Stockgard, Uppman, et al; Nature Communications)
  di: Nelander, Sven
  Pubblicazione: (2025)